BRONTE, Giuseppe
 Distribuzione geografica
Continente #
NA - Nord America 171
EU - Europa 17
AS - Asia 13
OC - Oceania 1
Totale 202
Nazione #
US - Stati Uniti d'America 169
IT - Italia 10
CN - Cina 4
DE - Germania 4
HK - Hong Kong 3
CA - Canada 2
FR - Francia 2
IL - Israele 2
IQ - Iraq 2
AU - Australia 1
JP - Giappone 1
LB - Libano 1
SE - Svezia 1
Totale 202
Città #
Chicago 15
Buffalo 10
New York 9
Los Angeles 8
Ashburn 7
Henderson 7
Crugers 4
Dallas 4
Herndon 4
Miami 4
San Francisco 4
Denver 3
Houston 3
Portland 3
Seattle 3
Tolentino 3
Atlanta 2
Columbus 2
Edison 2
Erbil 2
Milwaukee 2
Providence 2
Rehovot 2
Rochester 2
Scottsdale 2
Anhui 1
Beirut 1
Castel Maggiore 1
Castelfidardo 1
Cedar Knolls 1
Cesena 1
Cheyenne 1
Council Bluffs 1
Dulles 1
Fremont 1
Heidelberg 1
Jersey City 1
Kirkland 1
Lombard 1
Marche 1
Melbourne 1
Memphis 1
Montreal 1
Munich 1
Omaha 1
Reston 1
Saint-Genest-Lerpt 1
Salem 1
San Benedetto del Tronto 1
San Jose 1
Santa Clara 1
Secaucus 1
Stockholm 1
Tokyo 1
Verona 1
Winnipeg 1
Totale 140
Nome #
EGFR genomic alterations in cancer: prognostic and predictive values, file e18b8791-e3c5-d302-e053-1705fe0a27c8 14
Cetuximab rechallenge in metastatic colorectal cancer patients: How to come away from acquired resistance?, file e18b8791-e3cc-d302-e053-1705fe0a27c8 7
Chronological age or biological age: What drives the choice of adjuvant treatment in elderly breast cancer patients?, file e18b8791-e3fe-d302-e053-1705fe0a27c8 7
Liquid biopsy for egfr mutation analysis in advanced non-small-cell lung cancer patients: Thoughts drawn from a real-life experience, file e18b8791-e65e-d302-e053-1705fe0a27c8 6
The impact of progesterone receptor expression on prognosis of patients with rapidly proliferating, hormone receptor-positive early breast cancer: a post hoc analysis of the IBIS 3 trial, file e18b8791-e880-d302-e053-1705fe0a27c8 6
Well-being among Italian medical oncologists: An exploratory study, file e18b8791-eac3-d302-e053-1705fe0a27c8 6
Corrigendum: Cetuximab rechallenge in metastatic colorectal cancer patients: How to come away from acquired resistance? [Ann Oncol, 23, 9, (2012) (2313-2318)] doi: 10.1093/annonc/mdr623, file e18b8791-e3ca-d302-e053-1705fe0a27c8 5
Case Report: Stevens-Johnson Syndrome and Hepatotoxicity Induced by Osimertinib Sequential to Pembrolizumab in a Patient With EGFR-Mutated Lung Adenocarcinoma, file e18b8791-ef36-d302-e053-1705fe0a27c8 5
The prognostic effects of circulating myeloid-derived suppressor cells in non-small cell lung cancer: systematic review and meta-analysis, file 152ae1b9-a7b5-46c1-a547-cf48ba66efa0 4
The cell line models to study tyrosine kinase inhibitors in non-small cell lung cancer with mutations in the epidermal growth factor receptor: A scoping review, file cc37c52d-8610-4d2c-8410-9d44a494c466 4
Semi-automated volumetric analysis in the NELSON trial for lung cancer screening: Is there room for diagnostic experience yet, file e18b8791-e5ac-d302-e053-1705fe0a27c8 4
Petals and thorns in programmed death-ligand 1 testing: Is all non–small cell lung cancer diagnostic material suitable?, file e18b8791-e6a2-d302-e053-1705fe0a27c8 4
New generation anaplastic lymphoma kinase inhibitors, file e18b8791-e71f-d302-e053-1705fe0a27c8 4
Multisciplinary management of patients with liver metastasis from colorectal cancer, file e18b8791-e844-d302-e053-1705fe0a27c8 4
The Role of TP53 Mutations in EGFR-Mutated Non-Small-Cell Lung Cancer: Clinical Significance and Implications for Therapy, file e18b8791-ec57-d302-e053-1705fe0a27c8 4
Stabilizing versus destabilizing the microtubules: A double-edge sword for an effective cancer treatment option?, file e18b8791-edfe-d302-e053-1705fe0a27c8 4
Prognostic relevance of objective response according to EASL criteria and mRECIST criteria in hepatocellular carcinoma patients treated with loco-regional therapies: A literature-based meta-analysis, file e18b8791-ee07-d302-e053-1705fe0a27c8 4
Real-World Outcomes and Treatments Patterns Prior and after the Introduction of First-Line Immunotherapy for the Treatment of Metastatic Non-Small Cell Lung Cancer, file a983d805-f9f6-4190-a3fb-8cae3fa50fff 3
Targeting RET-rearranged non-small-cell lung cancer: Future prospects, file e18b8791-e296-d302-e053-1705fe0a27c8 3
Androgen receptor in advanced breast cancer: Is it useful to predict the efficacy of anti-estrogen therapy?, file e18b8791-e2b5-d302-e053-1705fe0a27c8 3
Are there differences in androgen receptor expression in invasive breast cancer in African (Tanzanian) population in comparison with the Caucasian (Italian) population?, file e18b8791-e2b7-d302-e053-1705fe0a27c8 3
Fully human antibodies for malignant pleural mesothelioma targeting, file e18b8791-e2bb-d302-e053-1705fe0a27c8 3
High-dose chemotherapy in a patient with coronavirus disease (COVID-19), file e18b8791-e2bd-d302-e053-1705fe0a27c8 3
HER2-positive male breast cancer: An update, file e18b8791-e35c-d302-e053-1705fe0a27c8 3
Hypoxia and human genome stability: Downregulation of BRCA2 expression in breast cancer cell lines, file e18b8791-e477-d302-e053-1705fe0a27c8 3
Analysis of tissue and circulating microRNA expression during metaplastic transformation of the esophagus, file e18b8791-e5a7-d302-e053-1705fe0a27c8 3
Imatinib dose escalation versus sunitinib as a second line treatment in KIT exon 11 mutated GIST: A retrospective analysis, file e18b8791-e5a9-d302-e053-1705fe0a27c8 3
Can KRAS and BRAF mutations limit the benefit of liver resection in metastatic colorectal cancer patients? A systematic review and meta-analysis, file e18b8791-e5ae-d302-e053-1705fe0a27c8 3
Concomitant TP53 mutation confers worse prognosis in EGFR-mutated non-small cell lung cancer patients treated with TKIs, file e18b8791-e5b3-d302-e053-1705fe0a27c8 3
The Interplay Between Programmed Death Ligand 1 and Vimentin in Advanced Non-Small-Cell Lung Cancer, file e18b8791-e5b4-d302-e053-1705fe0a27c8 3
Androgen Receptor Expression in Breast Cancer: What Differences Between Primary Tumor and Metastases?, file e18b8791-e6a0-d302-e053-1705fe0a27c8 3
Beyond evidence-based data: Scientific rationale and tumor behavior to drive sequential and personalized therapeutic strategies for the treatment of metastatic renal cell carcinoma, file e18b8791-e6e8-d302-e053-1705fe0a27c8 3
Advances in molecular mechanisms and immunotherapy involving the immune cell-promoted epithelial-to-mesenchymal transition in lung cancer, file e18b8791-e75d-d302-e053-1705fe0a27c8 3
Evaluation of Androgen Receptor in Relation to Estrogen Receptor (AR/ER) and Progesterone Receptor (AR/PgR): A New Must in Breast Cancer?, file e18b8791-e78a-d302-e053-1705fe0a27c8 3
Malignant Pleural Mesothelioma: State-of-the-Art on Current Therapies and Promises for the Future, file e18b8791-e7cc-d302-e053-1705fe0a27c8 3
Tmb in nsclc: A broken dream?, file e18b8791-e80c-d302-e053-1705fe0a27c8 3
The comparison of outcomes from tyrosine kinase inhibitor monotherapy in second- or third-line for advanced non-small-cell lung cancer patients with wild-type or unknown EGFR status, file e18b8791-e9d9-d302-e053-1705fe0a27c8 3
Progress with palbociclib in breast cancer: Latest evidence and clinical considerations, file e18b8791-e9de-d302-e053-1705fe0a27c8 3
MicroRNAs in colorectal cancer stem cells: New regulators of cancer stemness?, file e18b8791-ea07-d302-e053-1705fe0a27c8 3
Role of liquid biopsy in oncogene-addicted non-small cell lung cancer, file e18b8791-ea4d-d302-e053-1705fe0a27c8 3
Case Report: Circulating Myeloid-Derived Suppressive-Like Cells and Exhausted Immune Cells in Non-Small Cell Lung Cancer Patients Treated With Three Immune Checkpoint Inhibitors, file e18b8791-ea82-d302-e053-1705fe0a27c8 3
The Expression of Programmed Death Ligand 1 and Vimentin in Resected Non-Metastatic Non-Small-Cell Lung Cancer: Interplay and Prognostic Effects, file e18b8791-ea83-d302-e053-1705fe0a27c8 3
Adjuvant Chemoradiation Therapy in Gastric Cancer: Critically Reviewing the Past and Visualizing the Next Step Forward, file e18b8791-eb33-d302-e053-1705fe0a27c8 3
A phase II trial of fixed-dose rate gemcitabine plus capecitabine in metastatic/advanced biliary tract cancer patients, file e18b8791-ecc9-d302-e053-1705fe0a27c8 3
Monoclonal antibodies in gastrointestinal cancers, file e18b8791-ed8a-d302-e053-1705fe0a27c8 3
New findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: Do all roads lead to RAS?, file e18b8791-ee00-d302-e053-1705fe0a27c8 3
Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients, file e18b8791-ee01-d302-e053-1705fe0a27c8 3
What links BRAF to the heart function? New insights from the cardiotoxicity of BRAF inhibitors in cancer treatment, file e18b8791-ee03-d302-e053-1705fe0a27c8 3
PD-L1 expression as predictive biomarker in patients with NSCLC: A pooled analysis, file e18b8791-ef03-d302-e053-1705fe0a27c8 3
Nintedanib in NSCLC: Evidence to date and place in therapy, file e18b8791-ef33-d302-e053-1705fe0a27c8 3
Epithelial-to-mesenchymal transition and EGFR status in NSCLC: The role of vimentin expression, file e18b8791-ef79-d302-e053-1705fe0a27c8 3
High Levels of Circulating Monocytic Myeloid-Derived Suppressive-Like Cells Are Associated With the Primary Resistance to Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer: An Exploratory Analysis, file e18b8791-fc79-d302-e053-1705fe0a27c8 3
Novel therapeutic strategies for patients with NSCLC that do not respond to treatment with EGFR inhibitors, file e18b8791-f0e4-d302-e053-1705fe0a27c8 2
null, file 1c697e20-664f-45d0-b5c1-76e9c2e98c9b 1
Immunotherapy: Is a minor god yet in the pantheon of treatments for lung cancer?, file e18b8791-eac5-d302-e053-1705fe0a27c8 1
The application of cancer stem cell model in malignant mesothelioma, file e18b8791-f7c7-d302-e053-1705fe0a27c8 1
Totale 202
Categoria #
all - tutte 2.267
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 2.267


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20222 0 0 0 0 0 0 0 0 0 0 1 1
2022/2023193 53 6 5 52 4 7 26 33 3 4 0 0
2023/20247 0 0 0 2 0 0 0 2 1 2 0 0
Totale 202